FIND YOUR CONSULTANT
JOIN OUR COMMUNITY
FIND YOUR CONSULTANT
JOIN OUR COMMUNITY

Industries > 

Life Sciences > Vaccines, Biologics & Cell/Gene Therapy Practice

Vaccines, Biologics & Cell/Gene Therapy Practice

Umbrex connects companies in vaccines, biologics & cell/gene therapy to independent consultants with deep experience in the industry.

Over 90% of our Vaccines, Biologics & Cell/Gene Therapy Practice consultants are alums of McKinsey, Bain, or BCG.

Finding the right consultant should be this easy.

1

Tell us about your project

2

Interview candidates

(We’ll provide bios within 48 hours on average)

3

Select your consultant and start work!

Find a consultant in our Vaccines, Biologics & Cell/Gene Therapy) Practice

Prefer email? Write to [email protected]

Client Segments Umbrex Serves

  • Global vaccine manufacturers: Multinationals producing pediatric, adult and pandemic vaccines (mRNA, viral vector, protein); prioritize pipeline shaping, evidence, tendering, manufacturing resilience, cold-chain, and global access.
  • Large-molecule biologics innovators: Pure-play mAbs, bispecifics, ADCs, and recombinant protein developers; focus on portfolio strategy, CMC excellence, capacity, lifecycle management, payer access, and launch excellence globally.
  • Plasma-derived therapeutics companies: Operators of plasma collection and fractionation producing immunoglobulins and specialty proteins; optimize donor network, yields, capacity, regulatory, global supply, and pricing.
  • Cell therapy developers: Autologous/allogeneic CAR-T, NK, and TCR platforms; build scalable CMC, decentralized manufacturing, vein-to-vein orchestration, treatment-center networks, evidence, and reimbursement.
  • Gene therapy and genetic medicines developers: AAV, LV, gene-editing, and mRNA therapeutics (excluding prophylactic vaccines); advance platform, clinical development, manufacturability, durability analytics, regulatory, and launch/access.

Selected Capabilities of our Vaccines, Biologics & Cell/Gene Therapy Practice

Strategy & Corporate Development

  • Corporate And Platform Growth Strategy: Define ambition across vaccines, biologics, and cell and gene therapy; prioritize platforms like mRNA, adeno-associated virus, lentiviral, and allogeneic; set business models; drive profitable growth.
  • Research And Development Portfolio And Indication Prioritization: Prioritize pipeline using risk-adjusted net present value, probability of success, and capacity constraints; sequence indications and geographies; sharpen go no-go and capital allocation.
  • Build Buy Partner And Ecosystem Strategy: Design make buy partner choices for vectors, plasmids, lipid nanoparticles, and fill finish; structure academia and contract development and manufacturing partnerships; secure supply, speed, optionality.
  • Mergers Acquisitions And Licensing: Originate and evaluate targets and assets; run diligence on platforms and pipelines; structure business development and licensing deals; quantify synergies; accelerate inorganic growth.
  • Market Entry And Government Contracting Strategy: Design entry strategy for priority markets; shape procurement participation, advance purchase agreements, and partnerships; improve tender win rate, funding access, and national immunization program inclusion.

Operations

  • Biologics Manufacturing Excellence And Throughput Uplift: Deploy lean/TPM in upstream/downstream suites; optimize single‑use changeovers and campaign planning; raise OEE, yield, and batches per month; reduce COGS and deviations.
  • Aseptic Fill-Finish And Lyophilization Optimization: Redesign vial/syringe lines, lyophilizer loading, sterilization turnarounds, and visual inspection; lift OEE, first-pass yield, and sterility assurance; cut rejects, line downtime, and losses.
  • Quality Control Release Cycle Time Acceleration: Streamline QC labs—sample logistics, scheduling, automation, and review-by-exception; implement LIMS dashboards; shorten sterility, mycoplasma, and potency release; increase on-time batch disposition.
  • Cell Therapy Finite Scheduling And Throughput: Build finite-capacity schedules across apheresis receipt, expansion, harvest, fill, and cryo; synchronize QC and logistics; reduce vein-to-vein time, failures, idle time, and overtime.
  • Contamination Control And Annex 1 Operationalization: Redesign material and personnel flows, airlocks, cleaning and sanitization cycles, and EM execution; strengthen aseptic practices; reduce excursions, bioburden, and batch loss in GMP facilities.

Organization

  • Operating Model And Organizational Design: Redesign global product line and regional matrix with interfaces across research and development, quality, regulatory, and operations; set spans and layers; accelerate decisions and accountability.
  • Governance And Decision Rights Redesign: Establish design control and stage-gate governance, decision rights, and escalation across research and development, clinical, quality, and regulatory; cut rework, cycle time, and launch risk.
  • Global Business Services And Shared Services: Stand up shared services for finance, procurement, human resources, master data, and analytics; define service catalogs and service level agreements; reduce cost-to-serve, errors, and time-to-close.
  • Talent Strategy And Capability Building: Build talent strategy for systems engineering, software, quality, regulatory, manufacturing; create academies, career paths, and workforce plans; improve retention, capability depth, and leadership bench.
  • Performance Management And Incentive Architecture: Design key performance indicator (KPI) hierarchy, dashboards, and incentives aligned to quality, compliance, on-time launch, cost, and service; cascade goals; increase accountability and cross-functional performance.

Supply Chain

  • End-To-End Supply Chain Strategy And Network Design: Design drug substance and drug product network with multi-site manufacturing, 3PL distribution hubs, and postponement; cut cost-to-serve and lead time while improving on-time-in-full and resilience.
  • Integrated Business Planning And Demand Forecasting: Implement integrated business planning linking epidemiology, tenders, clinical and commercial demand; link planning to execution; improve forecast accuracy, fill rates, and inventory turns.
  • Cold Chain And Cryogenic Logistics Excellence: Design 2–8°C, -20°C, -80°C, and liquid nitrogen logistics with validated packaging and real-time sensors; ensure Good Distribution Practice compliance; cut excursions, spoilage, and freight cost.
  • Chain Of Identity And Chain Of Custody Orchestration: Implement digital chain-of-identity and chain-of-custody with apheresis scheduling, courier integration, and site coordination; reduce handoff errors, vein-to-vein time, and release delays.
  • Inventory Optimization And Single Use Materials Planning: Deploy multi‑echelon inventory optimization for resins, media, plasmids, filters, and single‑use assemblies; set buffers and allocation; lower stockouts, obsolescence, and working capital.

Procurement & Strategic Sourcing

  • Category Strategy And Sourcing Wave Deployment: Develop sourcing strategies for single‑use systems, chromatography resins, media, plasmids, viral vectors, lipid nanoparticles, vials, syringes; run competitive events; deliver PPV savings, assurance, lead‑time reduction.
  • CDMO, Plasmid, And Vector Sourcing Strategy: Select and contract CDMOs for drug substance, fill‑finish, plasmids, and viral vectors; secure reserved capacity, SLAs, and pricing; de‑risk tech transfer; cut COGS, lead time.
  • Long-Term Agreements And Allocation Management: Structure long‑term agreements with strategic suppliers; implement allocation governance, dual sourcing, and regionalization; increase continuity, shorten lead times, and protect supply during shortages.
  • Should-Cost Modeling And Specification Optimization: Build should‑cost models for single‑use assemblies, resins, media, plasmids, and vials; challenge specifications and tolerances; negotiate TCO reductions and savings without compromising GMP performance.
  • Supplier Qualification, QAAs, And SRM: Implement supplier qualification, quality agreements, and supplier relationship management; conduct risk scoring and audits to GMP and Annex 1; improve OTIF, quality, and continuity.

Organization

  • Operating Model And Organizational Design: Redesign platform‑ and site‑based structures across R&D, CMC, MS&T, manufacturing, Quality Assurance, Quality Control, and supply; clarify global–site decision rights; accelerate GMP decisions and accountability.
  • MS&T And Tech Transfer Organization Build: Establish Manufacturing Science and Technology function, tech transfer governance, roles, and playbooks; resource PPQ; shorten validation timelines and increase right‑first‑time transfers.
  • Global Quality Governance And QP Model: Define corporate and site Quality Assurance/Quality Control governance, Qualified Person release responsibilities, escalation paths, and audit committees; reduce findings, batch release delays, and compliance risk.
  • GMP Capability Academy And Workforce Planning: Build capability academies for aseptic behaviors, contamination control, deviation investigation, and LIMS; design shift models and staffing; cut deviations, overtime, and attrition; raise Annex 1 readiness.
  • Performance Management And Tiered Daily Management: Implement KPI hierarchy, tiered huddles, visual management, and problem‑solving routines across suites and labs; improve throughput, right‑first‑time, and on‑time batch disposition.

Marketing

  • Brand And Value Proposition Strategy: Define differentiated value propositions for vaccines, biologics, and cell and gene therapies; align approved claims, outcomes, and safety; drive provider preference, adoption, and share.
  • Launch Planning And Go-To-Market: Orchestrate launch planning, segmentation, and channel mix; integrate medical, access, and supply readiness; accelerate healthcare professional education, patient starts, and early revenue.
  • Healthcare Professional And Patient Omnichannel Demand Generation: Build compliant omnichannel programs across SEO, paid search, email, and portals using consented data and customer relationship management (CRM); increase leads, referrals, conversions, and adherence.
  • Cell And Gene Therapy Site Activation And Referral Marketing: Map referral pathways; segment target centers; build site toolkits, patient navigators, and education; increase referrals, time-to-treatment starts, and center productivity.
  • Tender And Immunization Program Marketing Enablement: Develop tender dossiers, burden of disease narratives, and key opinion leader endorsements for ministries, UNICEF, and Gavi; improve scores, awards, and inclusion in immunization programs.

Pricing

  • Global Price Architecture And Launch Sequencing: Set ex‑factory/WAC lists, net price corridors, affordability tiers, and launch sequencing to manage international reference pricing; protect price integrity and long‑term value.
  • Outcomes-Based And Innovative Contracting Design: Design outcomes‑based, annuity, warranty, and milestone contracts for cell and gene therapies and high‑cost biologics; align measures, data, and risk; expand access and net price.
  • Tender And Immunization Program Pricing Strategy: Build tender pricing ladders, bundle options, and supply commitments for UNICEF, Gavi, PAHO, and ministries; improve win rates, scores, and margin while managing capacity risk.
  • Gross-To-Net Optimization And Accrual Accuracy: Map gross‑to‑net waterfall across rebates, chargebacks, distribution fees, returns, and write‑offs; fix contract terms and accruals; reduce leakage and improve earnings predictability.
  • Price Governance And Deal Desk Enablement: Stand up governance and deal desk for advanced therapies; define floors, approval matrices, analytics, and CPQ enablement; reduce discount variance, cycle time, and margin erosion.

Finance

  • Advanced FP&A And Scenario Planning: Build driver-based FP&A linking CMC, yield, capacity, and launch timing; enable scenario planning, forecasts, and cash runway visibility for vaccines, biologics, cell and gene therapy.
  • Biologics And Cell And Gene Therapy Costing And Profitability: Design cost models and lot-level costing for upstream/downstream, batch failures, and validation lots; analyze yield variances and SKU economics; improve COGS, margin, and mix decisions.
  • Revenue Recognition And Contract Accounting: Implement IFRS 15 and ASC 606 accounting for outcomes-based, annuity, and milestone contracts; govern variable consideration, returns, and rebates; ensure compliant revenue, accruals, and disclosures.
  • Grants Incentives And Non Dilutive Funding Strategy: Secure BARDA, CEPI, and local incentives; optimize R&D tax credits and orphan designations; structure advance purchase agreements; extend cash runway and reduce cost of capital.
  • Tax And Transfer Pricing For Advanced Therapies: Design IP ownership and transfer pricing models for drug substance and fill finish; comply with OECD BEPS and Pillar Two; reduce tax rate and risk.

AI, Data & Analytics

  • GxP Data Strategy And Governance: Design enterprise data model, lineage, and governance for GxP (good practice) data; ensure ALCOA+, FAIR, and audit readiness; enable analytics reuse and compliant decision-making.
  • Bioprocess Advanced Analytics And Digital Twin: Build multivariate models and digital twins for upstream/downstream; deploy soft sensors and model predictive control; increase yield, reduce deviations, and stabilize critical quality attributes.
  • Real-Time Release And PAT Modeling: Develop chemometric models using near‑infrared (NIR), Raman, and Process Analytical Technology; enable real‑time release testing, faster disposition, fewer QC holds, and lower cost per batch.
  • Cell And Gene Therapy Orchestration Analytics: Optimize apheresis-to-infusion scheduling with machine learning; predict failures, manage chain-of-identity risk, and minimize vein‑to‑vein time across sites and couriers.
  • Vaccine Demand And Tender Forecasting Analytics: Integrate epidemiology, seasonality, tender calendars, and stockpiles into forecasting; improve supply planning accuracy, service levels, and capacity decisions.

Transformation

  • Enterprise Performance Transformation And EBITDA Uplift: Lead end-to-end transformation across vaccines, biologics, and cell therapy; prioritize value levers; execute sprints; deliver EBITDA uplift, COGS reduction, yield improvement, and cash acceleration.
  • Transformation Office And Value Capture: Stand up Transformation Office with workstreams, milestones, objectives and key results, and benefits tracking; enforce cadence and risk management; ensure synergy realization and on-time delivery.
  • Tech Ops And GMP Turnaround: Run cross-functional sprints to stabilize GMP performance—deviation backlog, CAPA effectiveness, batch release cycle time; recover service levels, compliance, and right‑first‑time.
  • Post Merger Integration And Carve-Out Execution: Execute integrations and carve-outs across platforms and sites; harmonize processes and systems; protect supply continuity; deliver revenue and cost synergies under strict GMP.
  • Working Capital And Inventory Reduction: Run cash acceleration across order-to-cash and forecast-to-fulfill; optimize campaign sizes, WIP, QC release; reduce DSO and inventory days; free cash.

Sustainability

  • Net Zero Strategy And Decarbonization Roadmap: Set science-based targets, baseline Scope 1/2/3, build marginal abatement cost curve; prioritize electrification, renewable power purchase agreements (PPAs), solvent recovery; deliver costed roadmap, governance, KPIs.
  • Scope 3 Supplier Engagement And Sustainable Procurement: Segment high-impact categories; set supplier emissions targets and specs; deploy scorecards and incentives; reduce Scope 3 Categories 1, 4, 9 while safeguarding quality and compliance.
  • Product Life Cycle Assessment And Eco-Design: Conduct life cycle assessments (LCAs) for drug substance and product; optimize packaging, packouts, materials; reduce carbon, water, waste without compromising sterility, stability, or safety.
  • Green Cold Chain And Logistics Decarbonization: Optimize modal mix, routing, and packouts; deploy reusable shippers and bio-based refrigerants; pilot sustainable aviation fuel (SAF); cut cold-chain emissions without compromising quality.
  • ESG Reporting And CSRD/ISSB Readiness: Design Environmental, Social, and Governance (ESG) data model; align to Corporate Sustainability Reporting Directive (CSRD) and International Sustainability Standards Board (ISSB); deliver assurance-ready reporting.

Compliance

  • Healthcare Compliance Program And HCP Engagement Governance: Design healthcare compliance program for vaccines, biologics, and cell and gene therapy; govern HCP interactions, Anti‑Kickback Statute, Open Payments; strengthen monitoring, training, and audit readiness.
  • Promotional Review And Advertising Compliance: Build medical‑legal‑regulatory review and claims governance for digital, field, and scientific exchange; ensure FDA/EMA promotional compliance and fair balance; reduce warning‑letter risk and cycle time.
  • Government Pricing And Contract Compliance: Establish government pricing compliance for Average Manufacturer Price, Best Price, Medicaid rebates, 340B, Veterans Affairs; automate calculations and audits; improve accrual accuracy and reduce penalties.
  • Data Privacy And Genetic Data Compliance: Design privacy governance for patient support and genomic data; align to GDPR and HIPAA; govern consent, de‑identification, data sharing, retention; reduce breach and enforcement risk.
  • Pharmacovigilance System And Safety Reporting Compliance: Strengthen pharmacovigilance system—case intake, individual case safety reports, signal management, periodic reports, REMS; ensure FDA/EMA reporting and inspection readiness for vaccines, biologics, and cell therapies.

Program & Portfolio Management

  • Portfolio Governance And Prioritization: Stand up portfolio governance across R&D and CMC; standardize stage gates and charters; prioritize by risk-adjusted value and constraints; increase throughput, on-time milestones, capital productivity.
  • Program PMO And Stage-Gate Delivery: Run integrated program plans aligning clinical, CMC, regulatory, quality, and supply; manage critical path and interdependencies; improve time-to-IND/BLA, submission quality, and launch readiness.
  • Resource And Capacity Portfolio Planning: Model constrained resources—vectors, plasmids, QC, suites, and people; optimize sequencing and staffing; reduce bottlenecks, overtime, and cycle time; maximize portfolio throughput.
  • Risk, RAID, And Benefits Realization: Implement RAID registers, risk burndown, early-warning KPIs, and benefits tracking; standardize mitigation plans; increase predictability, budget adherence, and benefits realization.
  • Launch And Tech Transfer Cutover Orchestration: Orchestrate IND/BLA to commercial cutover and tech transfer milestones across internal sites and CDMOs; run rehearsals and war rooms; hit PPQ, validation, and launch timelines.

Information Technology

  • ERP Transformation And S/4HANA Template: Design and deploy SAP S/4HANA template for vaccines, biologics, and cell therapy—batch genealogy, QC integration, serialization, and CMO connectivity; improve traceability, close speed, and control.
  • MES And Electronic Batch Record Deployment: Select and implement MES with electronic batch record and recipe management; integrate equipment and historians; increase right‑first‑time, release velocity, and Annex 1/GMP compliance.
  • Lab Informatics And LIMS/ELN Integration: Deploy LIMS, ELN, and Lab Execution System with instrument integration and e‑signatures; streamline sample management and stability; cut QC cycle time and data integrity risks.
  • DSCSA Serialization And Traceability Systems: Implement serialization, aggregation, and repositories for DSCSA (Drug Supply Chain Security Act); integrate CMOs and 3PLs; improve recall readiness, diversion detection, and compliance.
  • GxP Cloud And Integration With CSA: Stand up validated GxP cloud and integration (iPaaS/ESB) with CDMO B2B links; apply Computer Software Assurance; accelerate releases, reduce validation burden, and strengthen resilience.

Capital Projects

  • Capex Portfolio Strategy And Governance: Prioritize multi‑site capacity and risk‑adjusted returns; institute stage‑gate governance and funding controls; align CapEx to platform growth while safeguarding GMP continuity and resilience.
  • Facility Master Planning And Site Selection: Develop master plans and select sites considering utilities, workforce, incentives, biosafety levels, and logistics; optimize footprint, expansion phases, and compliance; reduce time‑to‑build and installed cost.
  • Front-End Loading And Basis Of Design: Run FEL 1‑3 and user requirements; choose single‑use versus stainless, modular cleanrooms, and skid packages; produce design basis, layouts, and cost estimates to de‑risk delivery.
  • EPCM Strategy And Contracting: Select EPC/EPCM partners; design contracting model, incentives, and KPIs; govern change orders and interfaces; improve schedule adherence, cost predictability, and quality on GMP builds.
  • Project Controls And CQV Orchestration: Stand up project controls, earned value, and schedule risk; coordinate commissioning, qualification, and validation per ASTM E2500; accelerate PPQ, minimize deviations, and hit handover milestones.

CMC & Tech Transfer

  • Process Development And Characterization: Build Quality by Design with scale‑down models; map critical parameters for mRNA, viral vector, monoclonal, and cell therapy; deliver validation‑ready, high‑yield processes.
  • Analytical Method Development And Validation: Develop and validate potency, purity, identity, and safety assays for vaccines, biologics, and cell therapy; shorten release timelines, reduce out‑of‑specification events, and strengthen comparability.
  • Control Strategy And Continued Process Verification: Define critical quality attributes, process controls, and specifications; implement Stage 3 continued process verification with statistical monitoring; ensure validation success, stable performance, and fewer deviations.
  • Tech Transfer And Process Performance Qualification: Plan and execute tech transfer to sites and contract development and manufacturing organizations (CDMOs); run process performance qualification (PPQ); meet timelines and first‑time‑right yields.
  • Comparability Strategy And Change Management: Design comparability protocols for scale, site, raw material, or process changes; align analytics and acceptance criteria; secure approvals quickly while minimizing revalidation and supply risk.

Quality Management Systems

  • Quality System Design And Harmonization: Design and harmonize GMP quality systems to ICH Q10, EU GMP, 21 CFR 210/211/600; standardize SOPs and metrics; cut deviations, cycle time, and inspection findings.
  • Deviation, CAPA, And Change Control Optimization: Redesign deviation, CAPA, and change control; standardize root cause and effectiveness checks; implement eQMS; shrink backlog, cycle time, and recurrence in biologics and cell therapy.
  • Data Integrity And Computer Software Assurance: Stand up ALCOA+ data integrity program and Computer Software Assurance; remediate audit trails and access controls; reduce FDA/MHRA observations and inspection risk across GxP systems.
  • Batch Release And Review-By-Exception Enablement: Enable review-by-exception and real-time release controls; standardize batch record review, QP certification workflows, and metrics; accelerate disposition and improve right-first-time for vaccines and biologics.
  • Audit And Inspection Readiness And Remediation: Run readiness assessments, mock inspections, and remediation programs for FDA, EMA, MHRA; build governance, quality plans, and narratives; cut 483s, criticals, and warning-letter risk.

Regulatory Affairs & Submissions

  • Global Regulatory Strategy And Pathway Design: Define IND/CTA to BLA/MAA pathways, ATMP classification, and expedited programs (Breakthrough, Regenerative Medicine Advanced Therapy); align claims and evidence; compress review timelines globally.
  • CMC Dossier Authoring And eCTD Publishing: Author Modules 2/3 quality summaries, control strategy, comparability, stability, and validation; publish eCTD and manage lifecycle; reduce information requests and shorten BLA/MAA review cycles.
  • Health Authority Engagement And Meeting Management: Plan and run pre‑IND, Scientific Advice, and Type B/C meetings; craft briefing packages and rehearsal; align on endpoints and CMC; de‑risk questions and inspections.
  • Clinical And Safety Submissions And Labeling: Compile clinical modules, risk management plans, and REMS; design CCDS, USPI, and SmPC; manage safety labeling updates; secure approvals faster and maintain compliance across markets.
  • Post-Approval Lifecycle Management And Variations: Plan and file supplements and variations—PAS, CBE‑30, EU Type IA/IB/II; coordinate global change packages and commitments; minimize approval lead time and avoid supply disruptions.

Connect with the right consultant

Umbrex rapidly connects you with independent professionals who combine top‑tier consulting experience at firms such as McKinsey, Bain, Boston Consulting Group with hands‑on roles.

Find a consultant in our Vaccines, Biologics & Cell/Gene Therapy) Practice

Prefer email? Write to [email protected]